Clinical Core

临床核心

• 批准号: 8676247
• 负责人: DAVID S KNOPMAN
• 金额: $ 55.11万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8676247
• 关键词: Address; African American; Alzheimer' s Disease; Alzheimer' s disease risk; Area; Attention; Autopsy; Beds; Behavioral; Biological Markers; Brain; Brain imaging; C9ORF72; Cessation of life; Clinical; Clinical Trials; Cognition Disorders; Cognitive; Consent; DNA; Dementia; Development; Disease; Education; Enrollment; Evaluation; Event; Frontotemporal Lobar Degenerations; Genes; Genetic; Genetic Materials; Grant; Image; Impaired cognition; Individual; Industry; Institutional Review Boards; Investigation; Lewy Body Dementia; Lewy Body Disease; Minor; Minority; National Institute on Aging; Neurologist; Participant; Patients; Persons; Positioning Attribute; Positron-Emission Tomography; Procedures; Publications; Publishing; REM Sleep Behavior Disorder; Recruitment Activity; Research; Research Project Grants; Resources; Site; Sleep Disorders; Syndrome; Testing; Time; Work; abstracting; base; cerebrovascular; clinical Diagnosis; eligible participant; genetic analysis; improved; interest; mild cognitive impairment; neuropathology; neuropsychological; normal aging; outreach; pre-clinical; success; synucleinopathy; volunteer

PROJECT SUMMARY / ABSTRACT - CLINICAL CORE The Mayo ADRC Clinical Core recruits, evaluates and follows longitudinally persons with cognitive disorders as well as cognitively normal persons who serve as controls. The Clinical Core is led by 4 behavioral neurologists (one in Jacksonville and 3 in Rochester) who have considerable expertise in the cognitive syndromes of the Alzheimer's disease (AD) and non-Alzheimer degenerative spectrum, as well as the cerebrovascular spectrum. In the past 4 years, the Mayo ADRC has made significant contributions in the areas of genetics and imaging of AD, the genetics, imaging and clinical characterization of the syndromes of frontotemporal lobar degeneration, and the clinical and imaging characterization of Dementia with Lewy Bodies. We have participated in numerous national consortia for clinical trials (industry and ADCS), genetics (ADGC) and imaging (ADNI). We have had excellent success with recruiting and retaining our research participants. In the past 4 years, we have recruited African American participants into a variety of projects and trials. Moreover, in conjunction with our Outreach, Recruitment and Education Core, we have a great increase in the number of African American participants who have agreed to brain donation after death. Although we do not require autopsy consent from our participants, our overall autopsy rate was 54%. For the new grant cycle, we intend to continue our activities in these focus areas. Thus, our specific aims include recruiting and following persons in the AD degenerative spectrum, persons with Dementia with Lewy Bodies and persons with frontotemporal lobar degeneration (FTLD) spectrum from preclinical to dementia. We will also recruit cognitively normal volunteers who agree to undergo brain imaging and cognitively normal persons with sleep disorders such as REM Sleep Behavior Disorder that are known to be predictive of synucleinopathy. This latter group will be recruited in order to address an understudied area, namely the preclinical manifestations of Lewy Body Disease. Our interest in this unique group of individuals takes advantage of our longstanding involvement in both mild cognitive impairment and in the Lewy Body Disease spectrum. We will also devote the necessary resources and effort for enhancing our recruiting and following of African American normal volunteers and patients with disorders in the AD, DLB and FTLD spectra. In support of another of our aims, we will obtain DNA on cognitively normal, MCI and dementia participants (AD, LBD, FTLD) in order to supply ADRC-related genetics projects with genetic material. All of the persons who are recruited and followed by the Mayo ADRC will have an evaluation by a behavioral neurologist, a neuropsychological assessment battery that includes the UDS as well as additional procedures, and multimodal brain imaging for the majority of participants. The Clinical Core will continue to work closely with the Neuropathology Core and ADRC related projects that require clinical- pathological correlation.

项目摘要/摘要-临床核心 梅奥ADRC临床核心中心纵向招募、评估和跟踪认知障碍患者 以及作为对照的认知正常的人。临床核心由4名行为神经学家领导 (一个在杰克逊维尔，三个在罗切斯特)，他们在认知综合症方面拥有相当的专业知识 阿尔茨海默病(AD)和非阿尔茨海默病的退化谱，以及脑血管谱。 在过去的4年里，梅奥ADRC在遗传学和成像领域做出了重大贡献 AD，额颞叶变性综合征的遗传学、影像和临床特征， 路易体痴呆的临床和影像特征。我们已经参加了无数次 临床试验(工业和ADCS)、遗传学(ADGC)和成像(ADNI)的国家联合体。我们已经有了 在招募和留住我们的研究参与者方面取得了出色的成功。在过去的4年里，我们已经 将非裔美国人参与者招募到各种项目和试验中。此外，与我们的 外展、招聘和教育核心，我们非洲裔美国人的数量大幅增加 同意死后脑捐赠的参与者。尽管我们不需要验尸同意 我们的参与者，我们的总体尸检率为54%。对于新的赠款周期，我们打算继续我们的 这些重点领域的活动。因此，我们的具体目标包括招聘和跟踪广告中的人员 路易小体痴呆和额颞叶痴呆患者的退化谱 从临床前到痴呆的退行性变(FTLD)谱。我们还将招募认知正常的志愿者 谁同意接受大脑成像和认知正常的睡眠障碍患者，如快速眼动睡眠 行为障碍被认为是联核症的预兆。后一组人员将在#年招募。 以解决一个研究不足的领域，即路易体病的临床前表现。我们的 对这群独特的个人的兴趣利用了我们在这两个温和的领域的长期参与 认知障碍和路易体疾病谱。我们还将投入必要的资源 和努力加强我们对非裔美国人正常志愿者和患者的招募和关注 AD、DLB和FTLD光谱中的无序。为了支持我们的另一个目标，我们将在 认知正常、MCI和痴呆症参与者(AD、LBD、FTLD)以提供ADRC相关遗传学 使用遗传物质的项目。所有被招募并被Mayo ADRC跟踪的人都将拥有 行为神经学家的评估，一个神经心理评估小组，包括UDS AS 以及额外的程序，以及为大多数参与者进行的多模式脑成像。临床核心 将继续与神经病理学核心和ADRC相关项目密切合作，这些项目需要临床- 病理相关性。